AxoGen Inc. reported a first quarter loss of $19.6 million, or 38 cents per share, while adjusted earnings came in at 7 cents. Revenue reached $61.5 million, topping the $58.7 million expected by analysts surveyed by Zacks. The regenerative medicine company projected full-year revenue of $270 million. Shares are up 20% since the beginning of the year and have more than doubled over the past year. This story was generated by Automated Insights using data from Zacks Investment Research.
Prepared by Christopher Adams and reviewed by editorial team.
No left-leaning sources found for this story.
No right-leaning sources found for this story.
Comments